Abbott RDx Cardiometabolic
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Abbott RDx Cardiometabolic sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Abbott RDx Cardiometabolic: 14 sponsored US clinical trials, none currently recruiting.
Abbott RDx Cardiometabolic sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 1 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cardiovascular Surgery With Coronary Angiography, with 1 trials.
Top-decile sponsor footprint
Abbott RDx Cardiometabolic ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
14 total, page 1 of 1
Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU
NCT01294228
Multi-Markers In the Diagnosis of Acute Coronary Syndrome
NCT01134913
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
NCT00933738
Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
NCT01037270
User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
NCT01036646
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
NCT00946231
Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF
NCT00693745
Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy
NCT00693329
Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury
NCT00445809
Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement
NCT00415948
SHORTness of Breath In the Emergency Department (SHORTIE)
NCT00206830
Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT II)
NCT00206843
Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)
NCT00206856
BRAIN (Biomarker Rapid Assessment of Ischemic iNjury)
NCT00206908
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
How the Abbott RDx Cardiometabolic archive is shaped
14 indexed studies, none listed as recruiting (0% open); 13 completed (93%).
Phase mix: 1 late (III/IV) vs 1 early (I/II) (balanced across stages).
Top condition: Cardiovascular Surgery With Coronary Angiography (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Abbott RDx Cardiometabolic: archived-pipeline peers nationwide
Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Abbott RDx Cardiometabolic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 archived trials
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
- Aerin Medical · 14 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Abbott RDx Cardiometabolic page
14 registered trials is a research-attention snapshot, not an endorsement of Abbott RDx Cardiometabolic or any single study.
- None of Abbott RDx Cardiometabolic's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Cardiovascular Surgery With Coronary Angiography is the condition Abbott RDx Cardiometabolic studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cardiovascular Surgery With Coronary Angiography trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abbott RDx Cardiometabolic pipeline card: 14 registered trials from official public datasets.Report a data error.